| |
DP
|
AS + SP T1
|
AS + SP T2
|
AS + SP T3
|
|---|
|
N (enrolled)
|
59
|
61
|
100
|
83
|
|
d28
|
|
Successful follow-up
|
53
|
57
|
97
|
78
|
|
Reinfection
|
0
|
0
|
0
|
0
|
|
Analysed
|
53
|
57
|
97
|
78
|
|
Recrudescence
|
0
|
0
|
1
|
0
|
|
ACPR % (95 % CI)
|
100 (93.2–100)
|
100 (93.7–100)
|
99.0 (94.4–99.8)
|
100 (95.3–100)
|
|
d42
|
|
Successful follow-up
|
52
|
56
|
97
|
77
|
|
Recurrence: reinfection
|
0
|
0
|
3
|
1
|
|
Recurrence: unknown genotype
|
0
|
0
|
2
|
0
|
|
Analysed
|
52
|
56
|
92
|
76
|
|
Recrudescence
|
0
|
0
|
2
|
0
|
|
ACPR (95 % CI)
|
100 (93.1–100)
|
100 (93.6–100)
|
97.8 (92.4–99.4)
|
100 (95.2–100)
|
|
d56
|
|
Successful follow-up
|
50
|
52
| | |
|
Recurrence: reinfection
|
0
|
0
| | |
|
Recurrence: unknown genotype
|
0
|
0
| | |
|
Analysed
|
50
|
52
| | |
|
Recrudescence
|
0
|
0
| | |
|
ACPR (95 % CI)
|
100 (92.9–100)
|
100 (93.1–100)
| | |
- Successful follow-up indicates patients seen up to and including the corresponding time point. Recurrences due to reinfection and one patient in the AS + SP arm with P. vivax infection at d28 were censored from analysis
